biacore

News & Events - biacore

SpotBot Microarrayer now has Biacore Flexchip SPR Application Support.

Sunnyvale, CA, Tuesday, June 20, 2006– TeleChem announced today the widely used SpotBot Microarrayer now has specific application support for the Biacore Flexchip SPR analysis system. Biacore, which was recently acquired by GE Healthcare, is the current market leader in SPR (surface plasmon resonance) detection platforms. The combination of the SpotBot, 946 Micro Spotting Device, and Flexchip system empowers users to profile hundreds of proteins simultaneously in real time. To see screen shots of the application software click here. Applications include: kinetic profiling to select for further characterization, mapping binding domains and epitopes, assessing the binding contributions of post-translational modifications such as phosphorylation, methylation or acetylation, and ranking antibody candidates for early selection. The details of the software upgrade were worked out with experienced Biacore application specialists Michael Murphy and Brian Lang. The programs are now available for download to all SpotBot users at http://www.myspotbot.com.

About TeleChem International, Inc.
TeleChem is a privately owned company with products and services provided by three corporate divisions: Life Sciences (ArrayIt®), Chemicals, and Diagnostics (NGS-ArrayIt, Inc.). The Life Sciences division offers a complete line of products and services for the microarray industry, a high-technology sector that uses tiny glass “chips” to decipher the human genome. TeleChem’s patented microarray manufacturing technology (U.S. 6,101,946) and supporting products are used in more than 10,000 company and university laboratories worldwide. The Chemicals division provides import and export services and government contract manufacturing in the area of industrial chemicals for plastics, fire control, water treatment, agriculture, and industrial and institutional compounding. The Diagnostics Division (NGS-ArrayIt, Inc.) has recently received a landmark patent (U.S. 6,913,879) from the United States Patent Office for its revolutionary “multi-patient” genotyping technology, which allows as many as 100,000 patients to be tested on a single microarray. NGS-ArrayIt plans to begin offering its patented genotyping and disease diagnostics methods to current and new users in the form of testing kits, services and technology transfer licenses.

Media Contact
Paul Haje
Director of Public Relations
408-744-1331
Email: paul@ArrayIt.com